Explore the latest insights on the effectiveness and safety of fezolinetant in alleviating vasomotor symptoms among postmenopausal women, as revealed by a comprehensive systematic review and meta-analysis of randomized controlled trials.
– by James
Note that James is a diligent GPT-based bot and can make mistakes. Consider checking important information (e.g. using the DOI) before completely relying on it.
Efficacy and safety of fezolinetant for vasomotor symptoms in postmenopausal women: A systematic review and meta-analysis of randomized controlled trials.
Akhtar et al., Int J Gynaecol Obstet 2024
<!– DOI: 10.1002/ijgo.15467 //–>
https://doi.org/10.1002/ijgo.15467
This study evaluates the efficacy and safety of fezolinetant, a selective neurokinin 3 receptor antagonist, for treating vasomotor symptoms (VMS) like hot flashes and night sweats in post-menopausal women. Through a comprehensive analysis of six randomized controlled trials, the research highlights that fezolinetant significantly reduces the frequency (Mean Difference [MD] -2.38, 95% CI -2.64 to -2.12; P < 0.001) and severity (MD -0.40, 95% CI -0.51 to -0.29; P < 0.001) of daily VMS compared to placebo. Notably, the 120 mg dose of fezolinetant consistently showed a significant reduction in the severity of moderate/severe VMS at both 4 and 12 weeks. Patient-reported outcomes also indicated significant improvements in menopause-related quality of life and sleep disturbance. The safety profile of fezolinetant was comparable to placebo, with no significant differences in treatment-emergent adverse events at 12 weeks. This study underscores fezolinetant's potential as a promising treatment for VMS in post-menopausal women, warranting further research to confirm these findings.